Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Illinois at Chicago

About this trial

Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.

Eligibility criteria

Qualifiers

None

Disqualifiers

Already on dopamine agonist/antagonist therapy for another condition

Parkinson's disease

Lewy body dementia

Men with QTc > 450

Trial design

Treatments tested in this trial

  • Haloperidol

Treatment groups

100 Participants
are divided into 1 treatment group